IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

Xpplicant:

LEVANON Erez et al

Serial No.:

10/764,503

Filed:

January 27, 2004

For:

Methods And Systems For Identifying Naturally Occurring

Antisense Transcripts And Methods, Kits And Arrays Utilizing

Same

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1635

Attorney

\$ \$\tau\$ \$\tau

Docket: 26946

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Dated: May 2, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Let of 1995

Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Complete if Known					
				Applicati	on Number	10/764,503			
				Filing Da	ite	January 27, 2004			
STATEMENT BY APPLICANT (use as many sheets as necessary)					First Nan	ned Inventor	LEVANON Erez et al		
					Art Unit		1635		
					Examine	r Name			
Sheet		1	of	2	Attorney	Docket Number	26946		
				PATENT	DOCUM				
Examiner Initials*	Cite No. 1	Document Number		tion Date D-YYYY	A	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (if known)}							
					1				_
									\dashv
				·					
				-					\dashv
									\dashv
					-				_
	I				1		l		_
		T	FOREI	GN PATE	NT DOCU	JMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ : Number ⁴ : Kind Code ⁵ (if known) PCT WO 2004/104161			cation Date OD-YYYY	Name of Patentee Applicant of Cited Doo		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	1			02-12-	2004	Levanon et al.			口
	 								Ш

Initials*	No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T 6
	1	PCT WO 2004/104161	02-12-2004	Levanon et al.		\square
	-					H
						\Box
						H
Examine Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language

by the appropriate symbols as indicated on the document under wind standard ST. To it possess. Application is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/764,503 January 27, 2004 Filing Date INFORMATION DISCLOSURE First Named Inventor LEVANON Erez et STATEMENT BY APPLICANT al Group Art Unit 1635 (use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet Of 26946 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city T^2 Initials No. and/or country where published. 2 Milner et al. "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays", Nature Biotechnology, 15: 537-541, 1997. Vanhee-Brossollet et al. "Do Natural Antisense Transcripts Make Sense in Eukaryotes?", 3 Gene, 211: 1-9, 1998. Kumar et al. "Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher 4 Eukaryotes", Microbiology and Molecular Biology Reviews, 62(4): 1415-1434, 1998. Nemes et al. "The SCA8 Transcript Is An Antisense RNA To A Brain-Specific Transcript 5 Encoding A Novel Actin-Binding Protein (KLHL1)", Human Molecular Genetics, 9(10): 1543-1551, 2000. Neumann "Antisense Oligonucleotides In Neuroendocrinology: Enthusiasm And 6 Frustration", Neurochem. Int., 31(3): 363-378, 1997. 7 Zavadil et al. "An Antisense Transcript To SMAD5 Expressed In Fetal And Tumor Tissues", Biochemical and Biophysical Research Communications, 255: 668-672, 1999. ጸ Thrash-Bingham et al. "aHIF: Natural Antisense Transcript Overexpressed In Human Renal Cancer And During Hypoxia", Journal of the National Cancer Institute, 91(2): 143-151, 1999. 9 Seroussi et al. "Duplications On Human Chromosome 22 Reveal A Novel Ret Finger Protein-Like Gene Family With Sense And Endogenous Antisense Transcripts", Gnome Research, 9: 803-814, 1999.. 10 Korneev et al. "Neuronal Expression Of Neural Nitric Oxide Synthase (nNOS) Protein Is Suppressed by Antisense RNA Transcribed From An NOS Pseudogene", The Journal of Neuroscience, 19(18): 7711-7720, 1999. 11 Sharp "RNA Interference-2001", Genes & Development 15: 485-490, 2001. 12 Dolnik "Naturally Occuring Antisense RNA", Pharmacol. Ther. 75(3): 179-184, 1997. 13 Knee et al. "Regulation Of Gene Expression By Natural Antisense RNA Transcripts", Neurochemical International, 31(3): 379-392, 1997.

		_
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant's unique citation designation number (optional).

3. Applicant's unique citation designation number (optional).

3. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.